Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients

Received 3 September 2005; received in revised form 26 October 2005; accepted 29 October 2005.

Abstract

Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported. We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively. BCR–ABL transcripts were not detected after completion of primary therapy in two cases. All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation. All three patients have ongoing favorable responses to CML therapy.

Keywords: Chronic myeloid leukemia, Therapy-related leukemia, Chemo-radiotherapy, Autologous stem cell transplantation, Lymphoid malignancies

a Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA

b Clinical Cytogenetics Laboratory, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA

c Century Medical Group, Buffalo, NY, USA

Corresponding author. Present address: Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Tel.: +1 716 845 1051; fax: +1 716 845 3272.

PII: S0145-2126(05)00414-5

doi:10.1016/j.leukres.2005.10.015

12 of 21